Search research articles
Contact Us
Filters
Showing results (1151-1160 of 1,171) with videos related to
Page
of 118
Sort By:
Nature Communications
|
October 5, 2017
Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas
Huan Wang, Aaron Bender, Peng Wang, et al.
Journal of Clinical Epidemiology
|
February 17, 2009
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement
Julian Little, Julian P T Higgins, John P A Ioannidis, et al.
Neuron
|
June 14, 2025
Major-depressive-disorder-associated dysregulation of ZBTB7A in orbitofrontal cortex promotes astrocyte-mediated stress susceptibility
Sasha L Fulton, Jaroslav Bendl, Giuseppina Di Salvo, et al.
Nature
|
April 23, 2011
The auroral footprint of Enceladus on Saturn
Wayne R Pryor, Abigail M Rymer, Donald G Mitchell, et al.
Clinical Genitourinary Cancer
|
January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Cancer Cell
|
October 22, 2021
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
Anthony P Y Liu, Kyle S Smith, Rahul Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.
The Lancet. Oncology
|
June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
The Lancet. Oncology
|
May 21, 2018
Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial
Giles W Robinson, Vasilisa A Rudneva, Ivo Buchhalter, et al.
Clinical Genitourinary Cancer
|
September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor
Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Page
of 118
Search research articles
Search
Showing results (1151-1160 of 1,171) with videos related to
Sort By:
Page
of 118
Nature Communications
|
October 5, 2017
Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas
Huan Wang, Aaron Bender, Peng Wang, et al.
Journal of Clinical Epidemiology
|
February 17, 2009
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement
Julian Little, Julian P T Higgins, John P A Ioannidis, et al.
Neuron
|
June 14, 2025
Major-depressive-disorder-associated dysregulation of ZBTB7A in orbitofrontal cortex promotes astrocyte-mediated stress susceptibility
Sasha L Fulton, Jaroslav Bendl, Giuseppina Di Salvo, et al.
Nature
|
April 23, 2011
The auroral footprint of Enceladus on Saturn
Wayne R Pryor, Abigail M Rymer, Donald G Mitchell, et al.
Clinical Genitourinary Cancer
|
January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Cancer Cell
|
October 22, 2021
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
Anthony P Y Liu, Kyle S Smith, Rahul Kumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.
The Lancet. Oncology
|
June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
The Lancet. Oncology
|
May 21, 2018
Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial
Giles W Robinson, Vasilisa A Rudneva, Ivo Buchhalter, et al.
Clinical Genitourinary Cancer
|
September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor
Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Page
of 118